Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYC NASDAQ:KMDA NASDAQ:MCRB NASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$4.00-3.6%$4.67$3.95▼$9.18$278.89M1.54425,385 shs268,173 shsKMDAKamada$7.44-0.3%$8.00$6.50▼$9.35$427.87M0.8464,513 shs32,576 shsMCRBSeres Therapeutics$5.78+2.8%$7.73$5.31▼$29.98$55.89M0.1262,177 shs28,944 shsOCULOcular Therapeutix$8.97-0.3%$8.91$6.23▼$16.44$1.96B0.94.70 million shs785,974 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics+2.47%+0.97%-6.74%-18.15%-50.42%KMDAKamada+0.27%+3.04%-3.24%-16.09%+8.43%MCRBSeres Therapeutics-1.40%-10.51%-26.44%-40.15%-25.07%OCULOcular Therapeutix+0.56%+10.17%-1.86%+3.57%+2.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$4.00-3.6%$4.67$3.95▼$9.18$278.89M1.54425,385 shs268,173 shsKMDAKamada$7.44-0.3%$8.00$6.50▼$9.35$427.87M0.8464,513 shs32,576 shsMCRBSeres Therapeutics$5.78+2.8%$7.73$5.31▼$29.98$55.89M0.1262,177 shs28,944 shsOCULOcular Therapeutix$8.97-0.3%$8.91$6.23▼$16.44$1.96B0.94.70 million shs785,974 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics+2.47%+0.97%-6.74%-18.15%-50.42%KMDAKamada+0.27%+3.04%-3.24%-16.09%+8.43%MCRBSeres Therapeutics-1.40%-10.51%-26.44%-40.15%-25.07%OCULOcular Therapeutix+0.56%+10.17%-1.86%+3.57%+2.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.44Hold$14.00250.09% UpsideKMDAKamada 3.00Buy$12.0061.29% UpsideMCRBSeres Therapeutics 2.00Hold$22.00280.62% UpsideOCULOcular Therapeutix 2.79Moderate Buy$23.78165.23% UpsideCurrent Analyst Ratings BreakdownLatest OCUL, BCYC, KMDA, and MCRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026BCYCBicycle Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/18/2026MCRBSeres Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/15/2026KMDAKamada Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/6/2026OCULOcular Therapeutix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$30.005/5/2026OCULOcular Therapeutix Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.004/30/2026BCYCBicycle Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/21/2026OCULOcular Therapeutix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026OCULOcular Therapeutix HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.004/10/2026BCYCBicycle Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026BCYCBicycle Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$13.00 ➝ $12.003/27/2026MCRBSeres Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$72.86M3.83N/AN/A$8.79 per share0.45KMDAKamada$180.46M2.37$0.61 per share12.18$4.68 per share1.59MCRBSeres Therapeutics$790K70.82$1.10 per share5.25$4.89 per share1.18OCULOcular Therapeutix$51.95M37.79N/AN/A$3.07 per share2.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$218.96M-$3.15N/AN/AN/A-344.95%-35.74%-29.54%8/14/2026 (Estimated)KMDAKamada$20.20M$0.3521.2612.200.6811.21%7.73%5.41%8/12/2026 (Estimated)MCRBSeres Therapeutics$5.70M-$5.17N/AN/AN/AN/A-130.29%-35.35%8/5/2026 (Estimated)OCULOcular Therapeutix-$265.94M-$1.46N/AN/AN/A-558.24%-64.28%-48.15%8/4/2026 (Estimated)Latest OCUL, BCYC, KMDA, and MCRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026KMDAKamada$0.12$0.07-$0.05$0.07$46.72 million$45.24 million5/5/2026Q1 2026MCRBSeres Therapeutics-$1.88-$2.08-$0.20-$2.08$0.36 million$0.36 million4/30/2026Q1 2026BCYCBicycle Therapeutics-$0.6209-$0.87-$0.2491-$0.87$7.50 million$0.89 million3/18/2026Q4 2025BCYCBicycle Therapeutics-$1.00-$0.29+$0.71-$0.29$7.08 million$47.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/AKMDAKamada$0.192.55%N/A54.29%N/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A12.6612.66KMDAKamadaN/A3.331.90MCRBSeres TherapeuticsN/A1.651.65OCULOcular Therapeutix0.1214.8114.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%KMDAKamada20.38%MCRBSeres Therapeutics59.34%OCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics8.50%KMDAKamada36.10%MCRBSeres Therapeutics5.20%OCULOcular Therapeutix3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.81 million63.88 millionOptionableKMDAKamada36057.51 million36.75 millionOptionableMCRBSeres Therapeutics3309.68 million9.18 millionOptionableOCULOcular Therapeutix230218.96 million212.17 millionOptionableOCUL, BCYC, KMDA, and MCRB HeadlinesRecent News About These CompaniesOcular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?June 15 at 5:01 PM | fool.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 8, 2026 | americanbankingnews.comAssessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price VolatilityJune 6, 2026 | finance.yahoo.comOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.comOcular Therapeutix, Inc. to Participate in Clinical Trials at the Summit 2026 in Las VegasJune 4, 2026 | quiverquant.comQOcular Therapeutix™ to Participate in Clinical Trials at the Summit 2026June 4, 2026 | globenewswire.comOcular Therapeutix™ to Host Investor Day on June 17, 2026June 2, 2026 | globenewswire.comOcular Therapeutix (NASDAQ:OCUL) Insider Sells $15,235.60 in StockMay 29, 2026 | insidertrades.comOcular Therapeutix Shrinking The Burden Of BlindnessMay 28, 2026 | bloomberg.comAcuta Capital Sells 56% of Ocular Therapeutix Shares in Q1May 27, 2026 | finance.yahoo.comOcular Therapeutix Inc (OCUL)May 24, 2026 | investing.comWhat This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for InvestorsMay 20, 2026 | finance.yahoo.comOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 15, 2026 | globenewswire.comOcular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comDole posts downbeat Q1 earnings, joins Ocular Therapeutix and other big stocks moving lower in Monday's pre-market sessionMay 11, 2026 | msn.comOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8, 2026 | globenewswire.comOcular: SOL-1 Success Is Real, But Adoption Risks Keep Me At HoldMay 8, 2026 | seekingalpha.comOcular Therapeutix Starts SOL-X Trial As AXPAXLI Data And Valuation DivergeMay 8, 2026 | finance.yahoo.comOcular Therapeutix (OCUL) Gets a Buy from H.C. WainwrightMay 6, 2026 | theglobeandmail.comWhy Ocular Therapeutix (OCUL) Stock Is NosedivingMay 6, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCUL, BCYC, KMDA, and MCRB Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$4.00 -0.15 (-3.64%) As of 01:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Kamada NASDAQ:KMDA$7.44 -0.02 (-0.27%) As of 12:59 PM Eastern This is a fair market value price provided by Massive. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Seres Therapeutics NASDAQ:MCRB$5.78 +0.16 (+2.85%) As of 01:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Ocular Therapeutix NASDAQ:OCUL$8.96 -0.03 (-0.28%) As of 01:04 PM Eastern This is a fair market value price provided by Massive. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? This Golden Cross Could Send Urban Outfitters to New Highs Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
